Tertiary Lymphoid Structures Associated with Enhanced Anti-tumor Immunity and Favorable Prognosis in Cervical Squamous Carcinoma

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2024 May 6

PMID 38709170

Authors

Guohai Xiong

Jinmei Shan

Qingguo Chong

Yueqing Cui

Affiliations

Soon will be listed here.

Abstract

Background: Cervical squamous carcinoma (CESC) is the main subtype of cervical cancer. Unfortunately, there are presently no effective treatment options for advanced and recurrent CESC. Tertiary lymphoid structures (TLSs) are clusters of lymphoid cells that resemble secondary lymphoid organs; nevertheless, there is no summary of the clinical importance of TLS in CESC.

Methods: A large set of transcriptomic and single-cell RNA-sequencing (scRNA-seq) datasets were used to analyze the pattern of TLS and its immuno-correlations in CESC. Additionally, an independent in-house cohort was collected to validate the correlation between TLS and TME features.

Results: In the current study, we found that the presence of TLS could predict better prognosis in CESC and was correlated with the activation of immunological signaling pathways and enrichment of immune cell subpopulations. In addition, TLS was associated with reduced proliferation activity in tumor cells, indicating the negative correlation between TLS and the degree of malignancy. Last but not least, in two independent immunotherapy cohorts, tumors with the presence of TLS were more sensitive to immunotherapy.

Conclusion: Overall, TLS is related to an inflamed TME and identified immune-hot tumors, which could be an indicator for the identification of immunological features in CESC.

References

Liu Z, Meng X, Tang X, Zou W, He Y . Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma. Cancer Immunol Immunother. 2022; 72(6):1505-1521. PMC: 10198854. DOI: 10.1007/s00262-022-03310-5. View

Helmink B, Reddy S, Gao J, Zhang S, Basar R, Thakur R . B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020; 577(7791):549-555. PMC: 8762581. DOI: 10.1038/s41586-019-1922-8. View

Mei J, Cai Y, Wang H, Xu R, Zhou J, Lu J . Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy. Clin Immunol. 2022; 246:109204. DOI: 10.1016/j.clim.2022.109204. View

Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K . Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019; 16(12):1289-1296. PMC: 6884693. DOI: 10.1038/s41592-019-0619-0. View

Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

Sato Y, Silina K, van den Broek M, Hirahara K, Yanagita M . The roles of tertiary lymphoid structures in chronic diseases. Nat Rev Nephrol. 2023; 19(8):525-537. PMC: 10092939. DOI: 10.1038/s41581-023-00706-z. View

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Zhao H, Wang H, Zhou Q, Ren X . Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies. Cancer Biol Med. 2021; . PMC: 8610165. DOI: 10.20892/j.issn.2095-3941.2021.0029. View

10.

Mao W, Cai Y, Chen D, Jiang G, Xu Y, Chen R . Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer. JCI Insight. 2022; 7(18). PMC: 9675559. DOI: 10.1172/jci.insight.161940. View

11.

Bruno T . New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. Nature. 2020; 577(7791):474-476. PMC: 7523515. DOI: 10.1038/d41586-019-03943-0. View

12.

GeurtsvanKessel C, Willart M, Bergen I, van Rijt L, Muskens F, Elewaut D . Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med. 2009; 206(11):2339-49. PMC: 2768850. DOI: 10.1084/jem.20090410. View

13.

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View

14.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

15.

Wang X, Miao J, Wang S, Shen R, Zhang S, Tian Y . Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells. Mol Cancer. 2022; 21(1):133. PMC: 9214989. DOI: 10.1186/s12943-022-01596-8. View

16.

Mei J, Xu J, Yang X, Gu D, Zhou W, Wang H . A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis. Mol Cancer. 2021; 20(1):11. PMC: 7789157. DOI: 10.1186/s12943-020-01304-4. View

17.

Gide T, Quek C, Menzies A, Tasker A, Shang P, Holst J . Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019; 35(2):238-255.e6. DOI: 10.1016/j.ccell.2019.01.003. View

18.

Hayashi Y, Makino T, Sato E, Ohshima K, Nogi Y, Kanemura T . Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br J Cancer. 2023; 128(12):2175-2185. PMC: 10241865. DOI: 10.1038/s41416-023-02235-9. View

19.

Brunet M, Crombe A, Cousin S, Vanhersecke L, Le Loarer F, Bessede A . Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer. Ann Oncol. 2022; 33(10):1084-1085. DOI: 10.1016/j.annonc.2022.06.007. View

20.

Mei J, Fu Z, Cai Y, Song C, Zhou J, Zhu Y . SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers. iScience. 2023; 26(2):106027. PMC: 9932126. DOI: 10.1016/j.isci.2023.106027. View